Press Releases

Date	Title
4/5/13	Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
3/7/13	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments
3/4/13	Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates
2/21/13	Sarepta Therapeutics to Present at Cowen & Company 33rd Annual Healthcare Conference
2/20/13	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013
2/4/13	Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference
1/30/13	Statement From Sarepta Therapeutics on Stock Volatility
12/28/12	Sarepta Therapeutics to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference
12/21/12	Sarepta Therapeutics Enters Into Clinical Trial Agreement With the National Institutes of Health for Further Development of Influenza Drug
12/13/12	Sarepta Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

IR Menu